A key issue in cancer biology is whether oncogenic transformation of different cell types of origin within an adult tissue gives rise to distinct tumour subtypes that differ in their prognosis and/or treatment response. We now show that initiation of prostate tumours in basal or luminal epithelial cells in mouse models results in tumours with distinct molecular signatures that are predictive of human patient outcomes. Furthermore, our analysis of untransformed basal cells reveals an unexpected assay dependence of their stem cell properties in sphere formation and transplantation assays versus genetic lineage tracing during prostate regeneration and adult tissue homeostasis. Although oncogenic transformation of basal cells gives rise to tumours with luminal phenotypes, cross-species bioinformatic analyses indicate that tumours of luminal origin are more aggressive than tumours of basal origin, and identify a molecular signature associated with patient outcome. Our results reveal the inherent plasticity of basal cells, and support a model in which different cells of origin generate distinct molecular subtypes of prostate cancer.
consistent, given the distinct assays for stem cell properties that have been employed.
The cell-of-origin model for intertumour heterogeneity proposes that tumour initiation from distinct cell types in the lineage hierarchy gives rise to tumour subtypes with different prognoses and/or treatment responses 1, 15 . Although this model has received considerable support in studies of breast cancer 16 , it has not been systematically investigated in prostate cancer. However, several groups have investigated whether luminal cells or basal cells, or both, might serve as cell types of origin for prostate cancer. In particular, lineage-tracing analyses of CARNs have provided evidence that rare luminal cells can act as a cell of origin in vivo 14 , whereas other studies have shown that lentiviral overexpression of oncogenes in isolated mouse and human basal cells can give rise to tumours with luminal phenotypes in renal grafts, although luminal cells fail to generate tumours under these conditions 13, 17 . In addition, a recent study has shown that both luminal and basal cells can serve as cells of origin for prostate cancer, generating tumours that are histologically similar in mouse models 18 .
These previous studies have raised the possibility that ex vivo cell culture and tissue grafting assays may yield different results from in vivo lineage-tracing analyses. Therefore, we have undertaken a comprehensive analysis of prostate basal cell properties using genetic lineage marking to examine the properties of the identical cell population in multiple assays for stem cell function. Our results show that apparent discrepancies in the published literature can be explained by the considerable plasticity of basal cells in distinct functional assays. Moreover, although both basal and luminal cells can serve as cells of origin for prostate cancer, giving rise to tumours with similar histological phenotypes, our molecular and bioinformatic analysis shows that the luminal origin tumours are more aggressive, and identifies a molecular signature that has predictive value for human patient survival. Thus, our study supports the cell-of-origin model as a basis for distinct prostate cancer subtypes.
RESULTS

Analysis of lineage-marked prostate basal cells in cell culture and grafting assays
To provide a comprehensive analysis, we have performed genetic marking of prostate epithelial basal cells using a CK5-CreER T 2 transgenic line 19 in combination with the R26R-YFP reporter allele 20 for isolation of a purified cell population for sphere formation and tissue reconstitution assays and for lineage tracing in vivo. In control experiments, tamoxifen induction of hormonally intact CK5-CreER T 2 ; R26R-YFP/+ mice resulted in highly specific expression of YFP in 24.5% (n = 1,538/6,267) of CK5 + basal cells in the anterior prostate lobe, whereas no YFP-positivity was observed in non-basal cells (n = 0/15,846; Fig. 1a ); quantification for all experiments is detailed in Supplementary Table S1. We verified that the YFP-marked cells were positive for the basal cell markers p63 and CK14, and were mostly negative for the luminal marker CK18 ( Supplementary Fig. S1a ,e-n), and were detected at similar frequencies in the dorsolateral (23.2%) and ventral (24.9%) prostate lobes ( Supplementary Fig. S1c,d ). Furthermore, 1.6% of p63 + YFP + cells also expressed the luminal marker CK18 ( Supplementary Fig. S1o-s) , indicating that the marked population includes intermediate cells.
Next, we isolated lineage-marked YFP + cells by flow sorting of dissociated prostate cells from tamoxifen-induced CK5-CreER T 2 ; R26R-YFP/+ mice. Approximately 3.2% of total prostate cells were isolated in the YFP + fraction (Fig. 1b) , and greater than 98% of these isolated YFP + cells were CK5 + , p63 + and CK18 − ( Supplementary  Fig. S2a-l ). Furthermore, we compared this YFP + population to that of Lin − Sca-1 + CD49f hi cells, which have been previously characterized as a basal population enriched for stem/progenitor cells 8, 12 . Nearly all YFP + cells (98.7%) were contained in the Lin − CD49f + population, and 8.0% of the YFP + cells were present in the Lin − Sca-1 + CD49f hi fraction (Fig. 1c ). Conversely, we found that 24.4% of the Lin − Sca-1 + CD49f hi cells from tamoxifen-induced CK5-CreER T 2 ; R26R-YFP/+ mice were YFP + (Fig. 1d,e ), similar to the overall percentage of YFP + basal cells. These results indicate that the YFP + population includes Lin − Sca-1 + CD49f hi cells in a proportional and unbiased manner.
Using unsorted dissociated cells from tamoxifen-induced CK5-CreER T 2 ; R26R-YFP/+ prostate tissue in sphere formation assays, we found that approximately 23% of the resulting spheres were YFP + (Fig. 1f) , consistent with the overall percentage of marked basal cells. After flow sorting, 4.7% of the YFP + cells could form spheres that exhibited expression of basal and luminal markers ( Fig. 1g and Supplementary Fig. S2m -r), consistent with previous studies 8, 21 . This frequency of sphere formation was similar between the Lin − Sca-1 + CD49f hi YFP + cells and the remaining YFP + cells ( Supplementary Fig. S2s ), and was similar in mice at both 2 months and 12 months of age ( Fig. 1g ).
Tissue reconstitution assays have been used to show that Lin − Sca-1 + CD49f + and Lin − Sca-1 + CD49f hi Trop2 hi cells readily generate prostate ducts in renal grafts 8, 12 , but the overall efficiency of basal cells in this assay has not been previously determined. Therefore, we have used our highly purified YFP + population in prostate reconstitution assays, and have performed a limiting dilution analysis to determine the percentage of basal cells with reconstituting ability. This analysis shows that approximately 3.9% of basal cells contain graft-forming activity ( Fig. 1h ,i); these grafts exhibit their donor origin by expression of YFP, display prostatic histology and form ducts with luminal, basal and neuroendocrine cells ( Fig. 1j-o and Supplementary  Fig. S2t) . Notably, the similar efficiencies of tissue reconstitution (3.9%) and sphere formation (4.7%) raise the possibility that these two distinct assays may identify the same progenitor population.
Identification of rare bipotential basal cells during prostate regeneration in vivo
Using lineage tracing, we explored the properties of basal cells during prostate regeneration in vivo, using a protocol similar to one that we have previously employed 14 . We marked prostate basal cells by tamoxifen treatment of hormonally intact CK5-CreER T 2 ; R26R-YFP/+ mice, as in Fig. 1a , followed by androgen deprivation to induce prostate regression, and then androgen restoration to promote prostate regeneration ( Fig. 2a ). After regeneration, we found that most YFP + cells were basal, but 0.04% of YFP + cells were luminal (n = 5/11,427 cells; Fig. 2b-f and Supplementary Table S1 ). Notably, the percentage of basal cells exhibiting bipotentiality as detected by lineage tracing in vivo is significantly lower than the percentage exhibiting stem cell properties in sphere formation or tissue reconstitution assays (P < 0.0001; χ 2 test).
We next investigated whether this low detection rate of marked luminal cells might reflect an inherently low proliferation rate of basal cells (Fig. 2g,h and Supplementary Fig. S3 ). Using both Ki67 immunostaining and BrdU incorporation methods, we found that approximately 8.0% of basal cells proliferated during prostate regeneration (Fig. 2g,h and Supplementary Fig. S3 ). Furthermore, rare bipotential basal cells were observed at approximately 0.05% frequency using alternative regeneration protocols or in aged mice ( Supplementary Fig. S4 ). Taken together, these results indicate that the frequency of luminal cell generation by dividing basal cells is low but stable during regeneration in vivo (Supplementary Table S1 ).
Given these findings, we then investigated whether lineage-marked luminal progeny of basal cells would accumulate during serial rounds of androgen deprivation and androgen restoration to drive prostate regression and regeneration. We analysed the frequency of YFP + luminal cells among total YFP + cells after three and five rounds of serial regeneration, as well as after four rounds in the regressed state ( Fig. 2i-o) . We observed 0.6% marked luminal cells after three rounds and 3.4% after five rounds ( Fig. 2j-l were analysed for each experiment. See Supplementary Fig. S3 and Table S1 for further data. (i) Lineage-tracing strategy during serial regression and regeneration. (j-l,n) YFP + luminal cells (arrows) that co-express AR (k), Nkx3.1 (l) and CK18 (n) are more frequently observed after three rounds (j-l) and five rounds (n) of serial regeneration. (m) Castration-resistant luminal cells can be detected after four rounds of regression. (o) The frequency of luminal cells among total YFP + cells during regeneration in anterior prostate is 0.04% (n = 5 out of 11,427, 3 animals) after one round, 0.07% (n = 13 out of 18,025, 5 animals) after one round using an alternative protocol, 0.03% (n = 3 out of 10,249, 3 animals) after one round in 12-month-old mice, 0.6% (n = 56 out of 9,129, 3 animals) after three rounds, and 3.4% (n = 303 out of 8,875, 3 animals) after five rounds. The one-round frequencies are not statistically different, whereas P < 0.0001 for frequencies of different rounds by χ 2 test. See Supplementary Fig. S4 and Table S1 for further data. AP, anterior prostate; DLP, dorsolateral prostate. Scale bars, 50 µm (b-g,j-n). Error bars in h,o correspond to s.d. and show variability between animals.
YFP + cells with increasing rounds of regeneration, which is further supported by the detection of castration-resistant YFP + luminal cells in the regressed prostate after four rounds ( Fig. 2m ). Taken together, these results are consistent with a model in which a bipotential basal progenitor can give rise to luminal progeny with transit-amplifying characteristics. Supplementary Table S1 for further data. (h) Strategy for analyses of cell proliferation at three different ages in wild-type C57BL/6 mice. At 2 months, 6 months or 12 months of age, BrdU was administered for 12 days followed by analysis. (i-n) Analysis of co-localization of BrdU immunostaining with CK5 (i,k,m) or CK18 (j,l,n); arrowheads indicate BrdU + basal cells, and arrows indicate BrdU + luminal cells. Scale bars, 50 µm (b-e,i-n). Error bars in f,g correspond to s.d. and show variability between animals.
Identification of rare bipotential basal cells during prostate homeostasis in vivo
We also examined the generation of luminal cells by lineage-marked basal cells during prostate homeostasis, using tamoxifen induction at 2 months of age followed by a long chase period ( Fig. 3a ). As in our analysis of serial regeneration, we found that the frequency of YFP + luminal cells among all YFP + cells increased with time, as determined at 4 months (0.02%), 6 months (0.5%) or 12 months (3.0%) of age ( Fig. 3b-f ). However, using BrdU incorporation assays, we found that the proliferation rate in both basal (1.1%) and luminal (6.1%) compartments was relatively stable at 2, 6 and 12 months of age ( Fig. 3g-n) . These results suggest that low-frequency generation of luminal cells from a bipotential basal progenitor results in small clusters of lineage-marked luminal cells, owing to the higher proliferation rate of luminal cells during homeostasis. Furthermore, these findings indicate that basal cells exhibit bipotentiality during regeneration and tissue homeostasis at approximately similar frequencies.
Basal cells as a cell of origin for prostate cancer
Next, we investigated whether CK5 + basal cells can be a cell of origin for prostate cancer, using a conditional allele of the Pten tumour suppressor for inducible inactivation in mice, modelling one of the most frequent genetic alterations in human prostate cancer 22, 23 . We found that CK5-CreER T 2 ; Pten flox/flox ; R26R-YFP/+ prostates at 1 month following tamoxifen induction exhibited small foci of epithelial hyperplasia and Grade I prostatic intraepithelial neoplasia (PIN) lesions 24 in otherwise histologically normal glands (Fig. 4a,b and Supplementary Table S2 ). At this stage, we could detect phosphorylated Akt in basal cells, as expected after loss of Pten (Fig. 4f ). By 3 months after induction, these mice exhibited Grade II and III PIN lesions, and at 6 months they had Grade III and IV lesions (Fig. 4c,d and Supplementary Fig. S5 and Table S2 ). Interestingly, we observed increased cell proliferation in basal cells before PIN lesion formation ( Fig. 4g and Supplementary Table S2 ), and subsequently in the PIN/tumour lesions ( Fig. 4h ). Notably, even Fig. 4e and Supplementary Fig. S6a-n) , which have a luminal cell of origin. Consistent with a recent report 18 , we found that the overall histopathology of the luminal origin PIN/tumour lesions was very similar, but arose with a different time course. At 1 month after induction, the Nkx3.1 CreERT 2/+ ; Pten flox/flox ; R26R-YFP/+ mice exhibited Grade II and III PIN, resembling 3-month basal origin lesions ( Fig. 4c and Supplementary Fig. S6b and Table S2 ). Similarly, 3-month luminal origin tumours exhibited Grade III and IV PIN, resembling 6-month basal origin tumours (Fig. 4d,e and Supplementary Fig. S6c,d and Table S2 ). These histopathological similarities were further supported by marker analyses (Fig. 4h-k and Supplementary Fig. S6f-k ). However, we did note that CK5 + CK18 + cells occurred at low frequencies in all prostate lobes of basal origin lesions, but at higher frequencies in the anterior and dorsolateral lobes of luminal origin lesions (Fig. 4l,m and Supplementary Fig. S6l -n). Overall, basal origin tumours are histologically similar to luminal origin tumours, but arise more slowly, perhaps owing to differences in the starting number of cells undergoing transformation and/or an intrinsic delay due to luminal differentiation from basal cells.
A luminal origin molecular signature predicts patient survival
To determine whether basal and luminal origin tumours might exhibit molecular differences, we performed transcriptome analyses comparing PIN/tumour lesions from basal or luminal origins at time points at which they exhibited similar histopathological phenotypes. We used RNA-seq to profile prostate tissue from basal origin tumours of CK5-CreER T 2 ; Pten flox/flox ; R26R-YFP/+ mice that were uninduced (control), or at 3 or 6 months after tamoxifen induction, or from luminal origin tumours of Nkx3.1 CreERT 2/+ ; Pten flox/flox ; R26R-YFP/+ mice that were uninduced (control), or at 1 or 3 months after induction (6 mice per category). Principal components analysis demonstrated the reproducibility of the independent biological replicates ( Fig. 5a,b ). We then performed gene set enrichment analysis (GSEA) to compare initiation signatures for basal origin lesions (3 months versus control) and for luminal origin lesions (1 month versus control; Supplementary  Tables S3 and S4 ); a similar comparison was performed for progression signatures for basal origin (6 months versus 3 months) and luminal origin lesions (3 months versus 1 month) ( Supplementary Tables  S5 and S6 ). These comparisons demonstrated the strong reciprocal enrichment of the initiation as well as progression signatures (Fig. 5c,d) , indicating that basal and luminal origin tumours are globally similar at the molecular level.
Nonetheless, we could identify molecular differences between the luminal and basal origin signatures by applying bioinformatic subtraction of the similar components of their signatures. Thus, we generated a mouse expression signature containing genes upregulated in luminal origin lesions relative to basal origin lesions (luminal 3 months-basal 6 months), or conversely upregulated in basal origin lesions ( Supplementary Table S7 ). Next, we used a mouse-to-human cross-species approach to compare this mouse luminal versus basal signature to a human lethality signature generated using survival data in a Swedish watchful-waiting patient cohort 25 . We defined this lethality signature as a list of genes ranked by their differential expression between high-risk (death within 12 months, 6 samples) and low-risk (survival for more than 192 months, 12 samples) cases in this cohort ( Supplementary Table S8 ). Using GSEA, we found that genes overexpressed in luminal origin tumours were significantly enriched in genes upregulated in the lethality (high-risk) signature (Fig. 5e) . In contrast, genes overexpressed in the basal origin tumours exhibited no statistical enrichment in the human lethality signature (Fig. 5f ), suggesting that luminal origin prostate cancer is more aggressive than basal origin prostate cancer. Furthermore, we used the luminal versus basal origin signature to infer Gene Ontology-Biological Process (GO-BP) gene sets that were significantly upregulated or downregulated. We identified 57 such GO-BP categories (P < 0.05; Fig. 5g and Supplementary Table S9 ), including categories such as cell cycle mitotic, E2F-mediated regulation of DNA replication, and extension of telomeres, consistent with a more aggressive phenotype of luminal origin tumours.
Next, we investigated the clinical relevance of the 68 genes with significant contribution to the enrichment of the luminal origin upregulated signature in the human lethality signature (the leading edge in Fig. 5e and Supplementary Table S10 ). Interestingly, many of these 68 genes are upregulated in human prostate cancer, as shown by analysis of five human patient data sets 22, [26] [27] [28] [29] ( Supplementary  Fig. S6o and Table S10 ). We tested this luminal origin leading-edge signature (LOLES) with two different data sets from Memorial Sloan-Kettering Cancer Center 22, 30 , in which patients are characterized by their biochemical recurrence (BCR)-free survival time, representing the duration between prostatectomy and subsequent detection of rising serum prostate-specific antigen levels. Using k-means clustering, we could stratify the 79 primary tumour samples from the Glinsky data set 30 , and the 131 primary tumour samples from the Taylor data set 22 , into two groups with significant differences in BCR-free survival (logrank P = 0.0255, Fig. 5h ; log-rank P = 0.0245, Fig. 5i ). Furthermore, the LOLES successfully stratified 263 patients of the Swedish cohort (excluding the samples used to define the lethality signature) into two distinct groups with a statistically significant difference in mean survival time of 3.4 years at 50% survival (log-rank P = 0.0065, Fig. 5j ).
Finally, we examined whether the LOLES may have independent prognostic value compared with histological Gleason scoring, which remains the best prognostic marker for overall survival 31 . Indeed, C-statistics analysis using the Swedish watchful-waiting cohort revealed that the LOLES improves the prognostic value of the Gleason score from 0.76 (C = 0.76; 95% CI 0.72-0.80, P = 1.10 × 10 −39 ) to 0.82 (C = 0.82, 95% CI 0.77-0.84, P = 2.25×10 −80 ; Fig. 5k ). Taken together, our bioinformatic analysis shows that the LOLES is highly correlated with poor patient prognosis.
DISCUSSION
Using a lineage-marking approach to examine the same population in ex vivo and in vivo assays, we have shown that prostate basal cells exhibit distinct properties in different assays for stem cell function, and reconcile several aspects of previous work on prostate stem cells that have seemed to be discordant. Notably, studies using ex vivo cell culture and tissue reconstitution assays have identified prostate basal cells as stem cells 8, 12, 21 , but our analyses indicate that basal cells can exhibit substantial plasticity when removed from their endogenous tissue microenvironment. More generally, our work supports the notion that genetic lineage tracing in vivo, not transplantation-based assays, represents a gold standard for identification of physiologically relevant stem cells 32 , and that unexpected plasticity should be considered when interpreting the outcomes of other stem cell assays. In principle, the plasticity of prostate basal cells might be regulated by extrinsic or intrinsic factors. For example, stromal and/or luminal cells could inhibit basal cell plasticity, and Pten loss might confer independence from this inhibition, allowing formation of transformed luminal cells. Moreover, the embryonic urogenital mesenchyme employed in tissue reconstitution assays has potent reprogramming activity 33, 34 , and could perhaps reprogram adult prostate basal cells to an embryonic multipotent progenitor state. Another possibility is that basal cell plasticity may be intrinsically regulated by cellular proliferation, because the percentage of luminal progeny is approximately 1-2% of dividing basal cells during regeneration and adult homeostasis. Thus, in response to strong proliferative signals provided by embryonic urogenital mesenchyme in tissue reconstitution assays, or due to Pten inactivation, basal cells might generate increased numbers of luminal cells.
Our findings suggest an overall similarity in the functional properties of basal cells in the prostate to those in other ductal epithelial tissues. Recent lineage-tracing analyses of the mammary and sweat gland epithelium have shown that luminal and myoepithelial cells are maintained by distinct unipotent progenitors, and myoepithelial cells can generate luminal cells in fad pad transplantation assays 35, 36 . Our work, together with other recent studies 18, 37 , indicates that a similar lineage relationship exists in the prostate epithelium, and that the plasticity of myoepithelial/basal cells may be a conserved attribute of ductal epithelial tissues. Moreover, the plasticity of basal cells in the adult prostate epithelium may reflect their role as stem/progenitor cells that generate all epithelial cell types during organogenesis 38 , similar to basal progenitors in mammary and sweat gland development 35, 36 .
We have also detected rare prostate basal cells that exhibit bipotentiality during adult tissue regeneration and homeostasis, at a frequency similar to that of bipotential luminal CARNs in the regressed prostate 14 . This finding differs from the conclusions of a recent report that the prostate basal lineage is completely unipotent 18 . The basis for this discrepancy is unclear, but could be due to the different Cre drivers used, or the larger number of cells and rounds of regeneration analysed in this study. Notably, the existence of bipotential adult basal stem/progenitor cells is also supported by retrospective lineage analyses of human prostate tissue using mitochondrial DNA mutations 39, 40 . Taken together, our findings suggest that basal and luminal lineages are largely independent in the adult prostate, but rare basal and luminal stem/progenitor cells can potentially compensate for imbalances in cell number during regeneration and tissue homeostasis. One possible model is that rare basal (and luminal) stem/progenitor cells may reside at the top of an epithelial lineage hierarchy, and a larger subpopulation of basal cells, perhaps corresponding to transit-amplifying cells, can exhibit plasticity in sphere and tissue reconstitution assays (Fig. 6a) . Alternatively, basal cells may exhibit stochastic stem/progenitor properties, with a low probability in the adult prostate epithelium and a higher probability when explanted or transformed (Fig. 6b) , resembling the maintenance of interfollicular and esophageal epithelium by stochastic progenitors during homeostasis and wound repair 41, 42 .
In humans, prostate adenocarcinoma exhibits a strong luminal phenotype with relatively uniform histopathological characteristics, and lacks distinct histological subtypes. At the molecular level, there has been some success in classifying tumours on the basis of gene expression profiling 26, 43 , and distinct molecular subtypes may be identifiable by specific mutations and/or chromosomal rearrangements 22, 23, 44, 45 . Nonetheless, prostate cancer has previously seemed to differ from other human cancers in which distinct tumour subtypes are readily defined 16, [46] [47] [48] . However, although we find that basal and luminal origin tumours in mice are histologically similar, as also reported previously 18 , our mouse-to-human cross-species bioinformatic analysis has identified a molecular signature in luminal origin tumours that correlates with patient outcome. Thus, our analysis suggests that prostate tumours arising from different cell types of origin may have distinct prognostic outcomes and/or treatment responses.
A major clinical challenge in prostate cancer research has been to distinguish the minority of patients who will develop aggressive disease from those who have indolent cancer and require minimal treatment. Indeed, considerable variation in outcome can exist between tumours with identical Gleason scores 31 , indicating that intertumour heterogeneity exists among prostate cancers that are histologically indistinguishable. So far, it has been difficult to identify In the case of the basal lineage, bipotential stem cells are relatively rare (approximately 0.05%), whereas basal cells that can exhibit stem cell properties in sphere formation and tissue reconstitution assays are more common (approximately 4%), and perhaps might correspond to transit-amplifying cells. Oncogenic transformation of either luminal or basal cells by inactivation of Pten results in tumours with histologically similar luminal phenotypes, but tumours arising from basal cells first undergo basal cell proliferation and subsequently luminal differentiation. Tumours may arise from stem cells (dark red jagged arrows) or may also be derived from more differentiated cell types (light red jagged arrows). (b) In a stochastic progenitor model, basal cells within an intact prostate epithelium randomly exhibit stem/progenitor properties at very low frequencies (orange), giving rise to luminal cells and being capable of self-renewal. (Luminal cells could conceivably follow a similar stochastic progenitor model, but this is not shown.) After tissue dissociation, however, the probability of such random basal stem/progenitor cells may be greatly increased. Oncogenic transformation of normal basal cells and/or stochastic basal progenitors leads to luminal differentiation and tumour formation; however, it is unlikely that stochastic progenitors represent the sole cell of origin following Pten deletion, given the rarity of these progenitors versus the frequency of observed PIN lesions.
useful prognostic biomarkers to improve on Gleason scoring, despite considerable effort to identify molecular signatures that can successfully stratify aggressive from non-aggressive disease 25 . Our cross-species analyses suggest that the cell of origin may represent an important component in determining prostate cancer aggressiveness, and may therefore lead to the identification of successful biomarkers.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb2697 METHODS Mouse strains and genotyping. The Nkx3.1 CreERT 2 targeted allele 14 and CK5-CreER T 2 transgenic line 19 have been described previously. Genotyping was performed by PCR using tail genomic DNA, with the following primer sequences: Nkx3.1 wild-type allele, 5 -CTCCGCTACCCTAAGCATCC-3 and 5 -GACACTGTCATATTACTTGGACC-3 ; CreER T 2 allele, 5 -CAGATGGCGCGGC-AACACC-3 and 5 -GCGCGGTCTGGCAGTAAAAAC-3 ; Pten flox allele, 5 -ACTCAAGGCAGGGATGAGC-3 and 5 -GTCATCTTCACTTAGCCATTGG-3 ; R26R-YFP allele, 5 -GCGAAGAGTTTGTCCTCAACC-3 (mutated forward), 5 -GGAGCGGGAGAAATGGATATG-3 (wild-type forward) and 5 -AAAGTCGCTCTGAGTTGTTAT-3 (wild-type and mutated reverse).
Mouse procedures. Castration of adult male mice was performed using standard techniques, with the fully regressed state attained at 4 weeks after castration. For prostate regeneration, testosterone (Sigma) was dissolved at 25 mg ml −1 in 100% ethanol and diluted in PEG-400 to a final concentration of 7.5 mg ml −1 . Testosterone was administered for 4 weeks at a rate of 1.875 µg h −1 delivered by subcutaneous implantation of mini-osmotic pumps (Alzet). This regimen yields physiological levels of serum testosterone 49 .
For tamoxifen induction, mice were administered 9 mg tamoxifen (Sigma) suspended in corn oil per 40 g body weight, or vehicle alone for negative controls, by oral gavage once daily for 4 consecutive days, followed by a chase period of 14 days. BrdU (100 mg kg −1 ; Sigma) was administered by intraperitoneal injection twice daily for 12 consecutive days during regeneration or homeostasis to label proliferating cells.
Tissue collection and flow cytometry. For histological and immunofluorescence
analysis, individual prostate lobes or renal grafts were dissected and fixed in 4% paraformaldehyde for subsequent cryoembedding in OCT compound (Sakura), or fixed in 10% formalin followed by paraffin embedding. For RNA isolation and RNA-seq analysis, prostate tissues were quickly dissected, flash-frozen in liquid nitrogen and stored at −80 • C.
For flow cytometry, prostate tissues were dissected and minced to small clumps, followed by enzymatic dissociation with 0.2% collagenase I (Invitrogen) in DMEM media with 5% FBS for 3 h at 37 • C. Tissues were digested with 0.25% trypsin-EDTA (StemCell Technologies) for 1 h at 4 • C, passed through 21-to 26-gauge syringes and filtered through a 40-µm cell strainer to obtain single-cell suspensions. Dissociated prostate cells were suspended in Hanks' balanced salt solution modified/2% FBS. Cell sorting was performed on a BD FACS Aria II instrument in the Flow Cytometry Shared Resource of the Herbert Irving Comprehensive Cancer Center. Antibodies used for sorting of Lin − Sca-1 + CD49f hi cells are listed in Supplementary Table S11 .
Sphere formation assay. For sphere formation assays, dissociated cells were incubated in PrEGM medium (Lonza). For each sample, 40 µl of cell suspension was mixed with 60 µl cold Matrigel, and pipetted around the rim of a well of a 12-well plate. The plates were placed in a 37 • C CO 2 incubator for 30 min to allow the Matrigel to solidify. Warm PrEGM (800 µl) was then added to each well. The spheres were cultured and monitored for 7-10 days with 50% medium change every 3 days. For sphere differentiation experiments, the spheres were subsequently cultured in PrEGM medium with 10 −8 M dihydrotestosterone (DHT), and monitored for 6 days with 50% medium change every 2 days.
Tissue reconstitution assay. For limiting dilution analysis, 5,000, 100 or 20 dissociated YFP + cells obtained from tamoxifen-induced CK5-Cre ERT 2 ; R26R-YFP/+ mice were mixed with 2.5 × 10 5 dissociated urogenital sinus mesenchyme (UGM) cells from embryonic day 18.0 rat embryos. UGM cells were obtained from dissected urogenital sinus treated for 30 min in 1% trypsin, followed by mechanical dissociation and treatment with 0.1% collagenase B (Roche) for 30 min at 37 • C, and washing in PBS. Pelleted cell mixtures were resuspended in 10 µl of 1:8 collagen/setting buffer (10× Earle's Balanced Salt Solution (Life Technologies), 0.2 M NaHCO 3 and 50 mM NaOH), and gelatinized at 37 • C for 20 min. Tissue recombinants were cultured in DMEM/10% FBS supplemented with 10 −7 M DHT overnight, followed by transplantation under the kidney capsules of immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (Jackson Laboratory). Grafts were collected after 8-12 weeks of growth for analysis, and extreme limiting dilution analysis was performed as described previously 50 .
Histology and immunostaining. Haematoxylin-eosin staining was performed using standard protocols on 6 µm paraffin sections. Histological assessments were performed using a published classification of mouse PIN lesions 24 .
For immunohistochemical staining, 6 µm paraffin sections were deparaffinized in xylene, followed by boiling in antigen unmasking solution (Vector Labs). Slides were blocked in 10% normal goat serum (NGS; Vector Labs), and incubated with primary antibodies diluted in 10% NGS overnight at 4 • C. Secondary antibodies were obtained from Vectastain ABC kits (Vector Labs) and diluted 1:250. Signal was enhanced using the Vectastain ABC system and visualized with the NovaRed Substrate Kit (Vector Labs). Slides were counterstained with Harris modified haematoxylin (1:4 diluted in H 2 O; Fisher Scientific) and mounted with Clearmount (American MasterTech). Haematoxylin-eosin staining and immunohistochemical staining were imaged using a Nikon Eclipse E800 microscope equipped with a Nikon DXM1200 digital camera.
Immunofluorescence staining was performed using 6 µm cryosections, which were incubated in 3% H 2 O 2 and Antigen Unmasking Solution (Vector Labs), or culture plates for whole-mount staining of spheres fixed in 4% paraformaldehyde for 15 min. Samples were incubated with 10% NGS and primary antibodies diluted in 10% NGS overnight at 4 • C. Samples were then incubated with secondary antibodies (diluted 1:500 in PBST) labelled with Alexa Fluor 488, 555 or 647 (Invitrogen/Molecular Probes). Detection of Nkx3.1 was enhanced using tyramide amplification (Invitrogen/Molecular Probes) by incubation of slides with HRP-conjugated secondary antibody (1:100 dilution; Invitrogen/Molecular Probes), followed by incubation with tyramide 555 for 6 min. Slides were mounted with VECTASHIELD mounting medium with DAPI (Vector Labs). Immunofluorescence staining was imaged using a Leica TCS SP5 spectral confocal microscope. All primary antibodies and dilutions used are listed in Supplementary  Table S11 .
Cell numbers were counted manually using confocal ×40 and ×63 photomicrographs. Statistical analyses were performed using a two-sample t -test, χ 2 test or Fisher's exact test as appropriate. At least 3 animals for each experiment or genotype were analysed.
RNA sequencing. Total RNA from prostate tissues was isolated using the Nucleospin RNA II kit (Clontech). The quantity and quality of each sample were measured using an Agilent 2100 Bioanalyzer. RNA-seq analysis was performed by the Columbia Genomic Sequencing Core Facility. Fragments per kilobase of transcript per million mapped reads (FPKM) values for 22,310 genes were reported. Genes with missing values (count of 0) in more than 10% of samples were eliminated from the analysis. Missing values for the remaining genes were estimated by using impute.knn (impute package in R v2.11.1). The resulting data set of 14,063 genes was normalized by using the robust spline normalization (RSN) function of R-system v2.11.1 and was log transformed. Principal components analysis was performed on scaled data, where the data value was adjusted by subtracting its mean across all samples and dividing by its standard deviation, z = (x −mean)/s.d. Expression data are deposited in the Gene Expression Omnibus database under GSE39509.
Statistical data analysis. Differential expression was estimated using the Welch
t -test (t .test function in R v2.11.1). To compare two distinct signatures we used GSEA (ref. 51), where P value was estimated with 1,000 sample permutations. Foldchange analysis was performed on data regenerated by reverse log transformation. Kaplan-Meier curves were generated using the surv, survdiff and survfit functions from package survival in R. C-statistics analysis was conducted using the concordance index function from the R survcomp package. The multivariate Cox proportional hazards model analysis with the Gleason score and leading edge genes was computed using a multiplicative and additive model for defining an integrated risk score model.
Comparing initiation and progression genes for luminal and basal tumours.
To compare genes that are responsible for initiation in tumours of both origins, we compared the L1 versus Lc signature with the B3 versus Bc signature. The query signature was defined as a list of genes ranked by their differential expression in the B3 group (n = 5 samples) compared with the Bc group (n = 6 samples) and was divided into two tails: a positive tail containing the top 200 overexpressed genes in B3 compared with Bc, and a negative tail with the top 200 underexpressed genes in B3 compared with Bc. The target signature was defined between L1 (n = 6 samples) and Lc (n = 5 samples) groups ( Supplementary Tables S3 and S4 ). Statistical significance of the enrichment between the query signatures and the target signatures was computed separately for the positive and negative tails using GSEA. Analogous analyses were performed comparing L3 versus L1 with B6 versus B3 signatures ( Supplementary Tables S5 and S6 ).
Comparing a luminal versus basal origin mouse signature with a human lethality signature. The luminal versus basal mouse signature (Fig. 5e,f) was defined between L3 (n = 6 samples) and B6 groups (n = 6 samples). For comparison with human prostate cancer expression profiling data, mouse genes were mapped to their human orthologues using mouse-human orthologous relations from the Mouse Genome Informatics database (MGI, http://www.informatics.jax.org/). This resulted in reduction of 14,063 mouse genes and 6,144 human genes to the set of 4,629 genes common between the human and mouse platforms.
The human lethality risk signature was derived from the Swedish watchfulwaiting data set 25 , consisting of 281 prostate cancer samples from the cohort recruited in Sweden between 1977 and 1999. We defined the high-risk (aggressive) group as patients that survived less than 12 months (n = 6) and the low-risk (indolent) group as patients that survived for more than 192 months (n = 12).
Genes differentially expressed between mouse L3 and B6 tumours, P value 0.01, were compared to the human lethality signature using GSEA. (Genes that were differentially expressed between the mouse models and did not differentially change between L3 and Lc or between B6 and Bc were excluded.) We divided the mouse gene list into those corresponding to genes overexpressed in L3 relative to B6 tumours (192 genes), and those corresponding to genes overexpressed in B6 compared with L3 (187 genes). The statistical significance of enrichment between the mouse query genes and the human target signature was computed separately for the group up in L3 tumours and the group up in B6 tumours.
Defining tumour subtypes in human patients. We examined the expression of the 68 genes in the LOLES in 5 high-quality patient data sets in the Oncomine database 22, [26] [27] [28] [29] , and found 19 genes to be upregulated in prostate cancer relative to benign prostate tissue in at least 3 of the 5 data sets ( Supplementary Fig. S6o and Table S10 ). We used the LOLES to stratify the 79 primary tumour samples from the Glinsky data set 30 and the 131 primary tumour samples from the Taylor data set 22 . When multiple probes mapped to a single gene, the probe with the highest coefficient of variation was selected to represent the gene. To differentiate between aggressive and non-aggressive cases of prostate cancer, an event for the survival analysis was defined as a biochemical recurrence happening within five years. The LOLES classified these patients into high-risk and low-risk classes after k-means clustering with the kmeans function in R. The difference between these two classes was tested with respect to BCR survival time (Kaplan-Meier BCR-free survival curve) and the P value of this difference was computed with a log-rank test. For analysis of the Swedish cohort 25 , we avoided overfitting by excluding patients used to construct the high-risk or low-risk human lethality signature (6 high-risk and 12 low-risk samples), resulting in 263 samples.
Pathway analysis. Enrichment of the mouse L3 versus B6 signature in human biological pathways was evaluated by GSEA using pathways collected in the REACTOME (ref. 52) , KEGG (ref. 53) and BioCarta (http://www.biocarta.com/ genes/allpathways.asp) databases. We mapped mouse genes to human orthologues using mouse-human orthologous relations from the Mouse Genome Informatics database (http://www.informatics.jax.org/), and selected those mapped genes that appeared in at least one biological pathway, resulting in 9,945 unique genes.
Table S1 Supporting data for quantitation of basal cell properties. Table S11 Antibodies used in this study.
